GlassScriptPhysician profile
Solomon Owusu
NPI 1487723243
$6,787.65
in general payments reported to CMS, 2019-2025
34 companies · $597 in 2025
The $597 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $231 · 2021: $783 · 2022: $1,329 · 2023: $1,395 · 2024: $976 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,644.49 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $957.38 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $687.05 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $462.62 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $445.30 | 2022-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $311.69 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $292.20 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $280.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.58 | 2019-2024 | Xifaxan, Trulance, Cycloset |
| Lilly USA, LLC | $245.24 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $190.03 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $122.74 | 2019-2022 | |
| Abbvie INC. | $103.82 | 2022-2024 | |
| Dexcom, INC. | $96.17 | 2024-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $81.79 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $75.86 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $70.23 | 2021-2023 | Contrave |
| Mannkind Corporation | $69.57 | 2019-2021 | |
| Pfizer INC. | $47.68 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.72 | 2019 | |
| Scilex Pharmaceuticals INC. | $45.13 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $27.97 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $26.63 | 2019-2020 | |
| Exact Sciences Corporation | $24.66 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $24.46 | 2022 | |
| Althera Pharmaceuticals LLC | $20.73 | 2021 | |
| Sumitomo Pharma America, INC. | $19.75 | 2023 | Gemtesa |
| Verona Pharma, INC. | $18.27 | 2025 | Ohtuvayre |
| Intuity Medical INC | $17.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.00 | 2021 | |
| Intra-Sana Laboratories | $14.70 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Kowa Pharmaceuticals America, INC. | $14.63 | 2024 | Zoryve |
| Melinta Therapeutics, LLC | $14.60 | 2019 | |
| Mylan Specialty L.P. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Owusu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.